Cyteir Therapeutics (Cyteir Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cyteir Therapeutics's Operating Income for the three months ended in Sep. 2023 was $-5.17 Mil. Cyteir Therapeutics's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Cyteir Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cyteir Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Cyteir Therapeutics's Interest Coverage or its related term are showing as below:

CYTT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

CYTT's Interest Coverage is ranked better than
99.41% of 341 companies
in the Biotechnology industry
Industry Median: 144.99 vs CYTT: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cyteir Therapeutics Interest Coverage Historical Data

The historical data trend for Cyteir Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cyteir Therapeutics Interest Coverage Chart

Cyteir Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Interest Coverage

No Debt

Cyteir Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Coverage	Get a 7-Day Free Trial											No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Cyteir Therapeutics's Interest Coverage

For the Biotechnology subindustry, Cyteir Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyteir Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Interest Coverage falls into.

Cyteir Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cyteir Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Cyteir Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-48.17 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Cyteir Therapeutics had no debt ⁽¹⁾.

Cyteir Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, Cyteir Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-5.17 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Cyteir Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Cyteir Therapeutics (OTCPK:CYTT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Cyteir Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421

Website

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness	officer: General Counsel	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey	director	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong	director	69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven	10 percent owner	BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421